The bill
To direct the Secretary of Health and Human Services to establish a Lung Cancer Task Force, and for other purposes.
HR. 6319, 119th Congress β read as touching Hospitals & Health Systems.
Sponsored by
Rep. Gottheimer, Josh [D-NJ-5]
ID: G000583
Follow the money
The bill
HR. 6319, 119th Congress β read as touching Hospitals & Health Systems.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
29 itemised contributions to this sponsor, pulled from FEC filings.
Track this bill's progress through the legislative process
Latest Action
Invalid Date
π Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
No summary available
Rep. Gottheimer, Josh [D-NJ-5]
Congress 119 β’ 2024 Election Cycle
No PAC contributions found
No committee contributions found
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 52 nodes and 29 connections (60 secondary connections hidden)
Total contributions: $193,281
Showing top 21 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 3 helped.
Section 2(c)(1) directs the task force to examine disparities in lung cancer research, funding, and patient access to treatments, which could lead to recommendations that increase funding or improve access, benefiting hospitals and health systems that provide lung cancer care.
Section 2(c)(3) focuses on lung cancer screenings in the United States; increased screening could drive demand for diagnostic imaging devices (e.g., CT scanners) used in lung cancer detection, benefiting medical device manufacturers.
Section 2(d) includes recommendations for increasing Federal funding for lung cancer research, which could support drug development and clinical trials, benefiting pharmaceutical companies involved in lung cancer therapeutics.
For each industry this bill affects, here's what the sponsor (Rep. Gottheimer, Josh [D-NJ-5])received from donors associated with that industry during the 2022βpresent cycles. Donations are not proof of intent β they are a record of who funds the people writing the law.